Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pae, C.-U. | - |
dc.contributor.author | Wang, S.-M. | - |
dc.contributor.author | Lee, S.-J. | - |
dc.contributor.author | Han, C. | - |
dc.contributor.author | Patkar, A.A. | - |
dc.contributor.author | Masand, P.S. | - |
dc.date.accessioned | 2021-09-05T15:57:31Z | - |
dc.date.available | 2021-09-05T15:57:31Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1474-0338 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/100724 | - |
dc.description.abstract | Introduction: Evidence increasingly points to the potential development of harmful cardiac side effects concomitant with the use of a number of psychotropic drugs, primarily traditional antipsychotics and tricyclic antidepressants. Areas covered: The US Food and Drug Administration announced safety warnings associated with the use of citalopram with QT interval prolongation in 2011 and 2012. This paper explores the clinical background of QT interval prolongation, clinical data related to antidepressants and QT interval prolongation, the clinical implications of safety issues associated with the use of antidepressants and future research directions. Expert opinion: Currently available evidence proposes that citalopram may not be definitely associated with the increase of cardiac mortality, although it should be related with increase of QT prolongation. A firm consensus regarding the cardiac safety issues associated with antidepressants has to be established in near future. Hence, the choice of an individual antidepressant regarding cardiac safety issues should be based on multiple factors; clinicians may need to select the best available antidepressant for each individual based on that patient's vulnerability, the proven efficacy and safety of each agent and a reasonable benefit:risk ratio, based on currently available findings. © Informa UK, Ltd. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.subject | amfebutamone | - |
dc.subject | amitriptyline | - |
dc.subject | antidepressant agent | - |
dc.subject | citalopram | - |
dc.subject | duloxetine | - |
dc.subject | escitalopram | - |
dc.subject | fluoxetine | - |
dc.subject | mirtazapine | - |
dc.subject | nortriptyline | - |
dc.subject | paroxetine | - |
dc.subject | sertraline | - |
dc.subject | venlafaxine | - |
dc.subject | cardiotoxicity | - |
dc.subject | cardiovascular risk | - |
dc.subject | drug effect | - |
dc.subject | drug efficacy | - |
dc.subject | drug safety | - |
dc.subject | heart arrhythmia | - |
dc.subject | human | - |
dc.subject | QT prolongation | - |
dc.subject | review | - |
dc.subject | sudden cardiac death | - |
dc.subject | Antidepressive Agents | - |
dc.subject | Citalopram | - |
dc.subject | Long QT Syndrome | - |
dc.subject | Risk Factors | - |
dc.subject | United States | - |
dc.subject | United States Food and Drug Administration | - |
dc.title | Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, C. | - |
dc.identifier.doi | 10.1517/14740338.2013.840583 | - |
dc.identifier.scopusid | 2-s2.0-84892747205 | - |
dc.identifier.bibliographicCitation | Expert Opinion on Drug Safety, v.13, no.2, pp.197 - 205 | - |
dc.relation.isPartOf | Expert Opinion on Drug Safety | - |
dc.citation.title | Expert Opinion on Drug Safety | - |
dc.citation.volume | 13 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 197 | - |
dc.citation.endPage | 205 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | amfebutamone | - |
dc.subject.keywordPlus | amitriptyline | - |
dc.subject.keywordPlus | antidepressant agent | - |
dc.subject.keywordPlus | citalopram | - |
dc.subject.keywordPlus | duloxetine | - |
dc.subject.keywordPlus | escitalopram | - |
dc.subject.keywordPlus | fluoxetine | - |
dc.subject.keywordPlus | mirtazapine | - |
dc.subject.keywordPlus | nortriptyline | - |
dc.subject.keywordPlus | paroxetine | - |
dc.subject.keywordPlus | sertraline | - |
dc.subject.keywordPlus | venlafaxine | - |
dc.subject.keywordPlus | cardiotoxicity | - |
dc.subject.keywordPlus | cardiovascular risk | - |
dc.subject.keywordPlus | drug effect | - |
dc.subject.keywordPlus | drug efficacy | - |
dc.subject.keywordPlus | drug safety | - |
dc.subject.keywordPlus | heart arrhythmia | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | QT prolongation | - |
dc.subject.keywordPlus | review | - |
dc.subject.keywordPlus | sudden cardiac death | - |
dc.subject.keywordPlus | Antidepressive Agents | - |
dc.subject.keywordPlus | Citalopram | - |
dc.subject.keywordPlus | Long QT Syndrome | - |
dc.subject.keywordPlus | Risk Factors | - |
dc.subject.keywordPlus | United States | - |
dc.subject.keywordPlus | United States Food and Drug Administration | - |
dc.subject.keywordAuthor | Antidepressant | - |
dc.subject.keywordAuthor | Benefit | - |
dc.subject.keywordAuthor | Citalopram | - |
dc.subject.keywordAuthor | Depression | - |
dc.subject.keywordAuthor | QT interval prolongation | - |
dc.subject.keywordAuthor | Risk | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.